ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
In the Phase III SANOVO trial, Orpathys extended PFS to 24.8 months in IHC 3+ NSCLC, but tolerability may weigh as heavily as efficacy.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory